Posted inBiotechnology
Intratumoral anti-CTLA4 Plus IV anti-PD1 Safety
In a groundbreaking study published in Nature in 2026, researchers have unveiled compelling evidence on the intricate immune landscape underlying…
Posted inBiotechnology
Nerves in the Skin May Help Slow Melanoma Growth
In an intriguing twist to our understanding of tumor biology, a recent study conducted by researchers at Weill Cornell Medicine…
Posted inBiotechnology
How Eating Primes Immune Cells to Boost Future Responses
How Eating Primes Immune Cells for Future Responses In a groundbreaking study published in Nature, researchers at the University of…
Posted inGenetics
Adaptive, Agent-Oriented Control for Biomanufacturing Systems
Agentic AI goes beyond predictive and generative AI and, in biomanufacturing, has the potential to enhance efficiency by integrating with…
Posted inGenetics
Hopes Raised for More Sustainable Oligonucleotide Manufacturing
Large-scale manufacturing of oligonucleotides could become more environmentally friendly if the biotech industry can overcome the challenges of a promising…
Posted inGenetics
Milk Exosomes Transform Therapeutic Bioprocessing
Breast milk has long been understood as more than infant nutrition. It is a biologically active system packed with molecular…
Posted inGenetics
Supply Chain Digital Twins: An Evolution, Not a Breakthrough
Digital twins help optimize drug production processes by modeling the thousands of interactions that cells, raw materials, and reagents undergo…
Posted inGenetics
Loss of Smell Therapies Informed by Olfactory Receptor Spatial Mapping
Credit: Design Cells / iStock / Getty Images Plus A new study published in Cell titled, “A spatial code governs olfactory receptor…
Posted inGenetics
Circio Partners with TraffikGene Project to Advance Non-Viral circVec Delivery
Credit: Nopparit/Getty Images Oslo-based Circio, which is developing circular RNA expression technology for gene and cell therapy, agreed to collaborate…
Posted inBiotechnology
FDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death
The FDA has halted U.S. enrollment for Newron Pharmaceuticals’ phase 3 schizophrenia trial, following the death of a patient outside…